China Resources Pharmaceutical Group and leading United Kingdom-based probiotic company Cultech signed a comprehensive strategic cooperation agreement in Beijing on Jan 30 during UK Prime Minister Keir Starmer’s official visit to China.
“This is a historic occasion. I fundamentally believe that the more we engage, the more we exchange, the more we take advantage of the opening of access to opportunities, business architecture and other areas, the better we can build the mutual trust and respect,” Starmer said in a keynote speech at the forum.
The landmark event was attended by more than 300 guests from the political and business sectors of both nations.
ALSO READ: Beijing: British PM's visit to China achieves fruitful results
The signing ceremony was witnessed by UK Economic Secretary to the Treasury Lucy Rigby, while Ding Xingchen of China Resources Pharmaceutical Group and Matthew Birt from Cultech inked the accord.
The partnership between two prominent Chinese and British healthcare enterprises has profound significance. Industry observers say it’ll open a new chapter in the development of the healthcare business of both countries, deliver tangible outcomes for both sides through resource sharing and technical exchanges, and contribute to a healthier future for people across borders.
Cultech has long stood out in the global probiotic field for its proprietary Lab4 bacterial strains and clinically proven probiotic products, earning widespread acclaim for their reliability and efficacy.
Chinese mainland actress Zhang Yue, who serves as Cultech’s brand ambassador, was present at the event to show her support for cross-border cooperation.
As a high-level platform for bilateral economic and trade exchanges, the UK-China Business Forum has played a pivotal role in facilitating collaboration between the two nations in diverse fields. Against the backdrop of evolving global cooperation, the strategic tie-up between China Resources Pharmaceutical and Cultech not only reflects the strong willingness of enterprises from both sides to deepen cooperation but also sets a positive example for Sino-UK synergies in the healthcare industry, paving the way for mutual benefit and common development.
Leveraging China Resources Pharmaceutical’s distribution network and rich market experience in China, coupled with Cultech’s advanced R&D capabilities in probiotics, the partnership is expected to bring high-quality healthcare products and services to more consumers. It’ll also inject new vitality into the upgrading and development of the global medical-and-health industry.
Contact the writer at evanhuang@chinadailyhk.com
